Search Results - "VECHORKO, V. I."

New SARS-CoV-2 Omicron variant — clinical picture, treatment, prevention (literature review) by Vechorko, V. I., Averkov, O. V., Zimin, A. A.

“…Despite the decrease in the incidence rate, today the problem of a coronavirus disease 2019 (COVID-19) remains relevant on a global scale. Among the Severe…”
Get full text

Pulmonary Sequelae of COVID-19 in Patients With Lung Damage Over 75% (CT-4) by Komissarova, K. V., Godzenko, A. V., Doroshenko, D. A., Gordeev, I. G., Averkov, O. V., Vechorko, V. I.

“…Introduction: A number of studies uses severity of lung damage as a predictor of lung changes in the long-term period. Objective: To evaluate computed…”
Get full text

NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick scales as outcomes assessment tools for severe COVID-19 (pilot retrospective cohort study) by Vechorko, V. I., Averkov, O. V., Grishin, D. V., Zimin, A. A.

“…Aim . To study the predictive ability of the NEWS2, 4C Mortality Score, COVID-GRAM and qSOFA scales in predicting clinical outcomes in patients with severe…”
Get full text

Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients by Averkov, O. V., Vechorko, V. I.

“…Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and…”
Get full text

Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19 by Shkurnikov, M. Yu, Averinskaya, D. A., Komarov, A. G., Karbyshev, I. A., Speshilov, G. I., Shtinova, I. A., Doroshenko, D. A., Vechorko, V. I., Drapkina, O. M.

“…Numerous studies showed that diabetes mellitus (DM) increases the risk of death from COVID-19 by five times. It is generally accepted that the high lethality…”
Get full text

Relationship of Covid-19 Severity with SARS-CoV-2 NS8 Protein Mutations Depending on Virus Strain by Shkurnikov, M. Yu, Averinskaya, D. A., Komarov, A. G., Karbyshev, I. A., Speshilov, G. I., Shtinova, I. A., Doroshenko, D. A., Vechorko, V. I.

“…In mid-2021, the Delta strain of SARS-CoV-2 caused the third wave of the COVID-19 pandemic. Huge efforts have been devoted to studying the effect of its…”
Get full text

The Effect of Carriage of CYP3A53 and CYP3A422 Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 by TEMIRBULATOV, I. I., KRYUKOV, A. V., MIRZAEV, K. B., DENISENKO, N. P., ABDULLAEV, S. P., ZHIRYAKOVA, A. S., SHEVCHUK, Y. V., VECHORKO, V. I., AVERKOV, O. V., SYCHEV, D. A.

“…The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters…”
Get full text

Loop-Mediated Isothermal Amplification as a Promising Method for Mass COVID-19 Diagnostics by Makarova, J. A., Fomicheva, K. A., Osipyants, A. I., Shkurnikov, M. Yu, Pokryshchenko, A. A., Tonevitsky, E. A., Vechorko, V. I.

“…Real-time reverse-transcription polymerase chain reaction (RT-PCR) is currently the most popular method for early COVID-19 diagnostics. However, loop-mediated…”
Get full text

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change? by Averkov, O. V., Vechorko, V. I.

“…Primary percutaneous intervention (PCI) is a preferable reperfusion method in patients with STEMI. If on-time PCI is not possible, pharmacoinvasive approach is…”
Get full text

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study by Shevchuk, Yu. V., Kryukov, A. V., Temirbulatov, I. I., Sychev, I. V., Mirzaev, K. B., Denisenko, N. P., Abdullaev, Sh. P., Tuchkova, S. N., Vechorko, V. I., Averkov, O. V., Sychev, D. A.

“…Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during…”
Get full text

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review by Kryukov, A. V., Zhiryakova, A. S., Shevchuk, Yu. V., Matveev, A. V., Vechorko, V. I., Averkov, O. V., Glagolev, S. V., Temirbulatov, I. I., Mirzaev, K. B., Denisenko, N. P., Abdullaev, Sh. P., Sychev, D. A.

“…The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products…”
Get full text

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism by Averkov, O. V., Vechorko, V. I., Shapsigova, O. A.

“…The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of…”
Get full text

MODERN APPROACHES TO ANTICOAGULANT THERAPY OF PULMONARY EMBOLISM: FOCUS ON RIVAROXABAN by O. V. Averkov, V. I. Vechorko

“…The analytical article provides a modern state of the anticoagulant therapy in pulmonary thromboembolism. Major advantages and preferential use of direct…”
Get full text

COVID-19 infection after recent heart transplantation: a case report by Vechorko, V. I., Gordeev, I. G., Gubareva, E. V., Ryndyaeva, E. V., Averkov, O. V.

“…History of heart transplantation in combination with immunosuppressive therapy and acute viral respiratory infection overlay makes the patient difficult to…”
Get full text

Factors and mechanisms of arterial hypertension development in patients with atherosclerosis of lower limb arteries by Evsikov, E. M., Vechorko, V. I., Teplova, N. V., Zhapueva, M. H., Artamonova, N. G.

“…The article contains information about the frequency of development of arterial hypertension (AH), the features and causes of its development in patients with…”
Get full text

Randomized Comparison of Two Approaches to Initial Warfarin Dosing: Time in Therapeutic Range of International Normalized Ratio During Hospitalization by Mishchenko, L N, Averkov, Oleg V, Gordeev, I G, Levchuk, N N, Vechorko, V I

“…To perform a randomized, open-label comparison of average time in therapeutic range (TTR) of international normalized ratio (INR) using two approaches to…”
Get more information

Plasma Level of hsa-miR-619-5p microRNA Is Associated with Prostatic Cancer Dissemination beyond the Capsule by Shkurnikov, M. Yu, Makarova, Yu. A., Knyazev, E. N., Fomicheva, K. A., Galatenko, A. V., Nyushko, K. M., Galatenko, V. V., Vechorko, V. I., Alekseev, B. Ya

“…Profiles of circulating microRNA in the plasma of patients with prostate cancer with pathomorphological stages pT2, pT3, and pT4 are analyzed. The level of…”
Get full text

MALIGNANT HYPERTENSION WITH PREDOMINANT KIDNEY DAMAGE by Lapochkina, N. D., Mamedguseyinova, S. S., Korsakova, L. V., Vechorko, V. I., Otarova, S. M., Gordeev, I. G.

“…The article is on a clinical case of malignant arterial hypertension in predominant kidney damage in a young man with disease anamnesis lasting 17 years…”
Get full text

Role of ACE2/TMPRSS2 genes regulation by intestinal microRNA isoforms in the COVID-19 pathogenesis by Nersisyan, SA, Shkurnikov, MYu, Osipyants, AI, Vechorko, VI

“…Coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, enters the cell by binding the cell surface proteins: angiotensin-converting enzyme 2 (ACE2) and…”
Get full text

LIFE QUALITY IN ONE YEAR AFTER MYOCARDIAL INFRACTION WITH INCOPLETE REVASCULARIZATION by Semiokhina, A. S., Taratukhin, E. O., Bayandin, N. L., Gordeev, I. G., Vechorko, V. I.

“…Aim. Life quality is an integral parameter of medical care efficacy. In incomplete revascularization after myocardial infarction the quality of life might…”
Get full text